

**TRINITY MOTHER FRANCES HOSPITALS AND CLINICS - TYLER, TEXAS**

ICU COMBINED ANTIBIOGRAM

**% SUSCEPTIBLE**

DATE RANGE:

JANUARY 2013 TO DECEMBER 2013

Aerobic Organisms  Gram POSITIVE	Number of Isolates	Clindamycin	Erythromycin	Levofloxacin	Nitrofurantoin (c)	Penicillin G	Oxacillin	Rifampin	Tetracycline	Trimeth/sulfa	Vancomycin
	#	%	%	%	%	%	%	%	%	%	%
Staph aureus	180	65(a)	39	-	-	12	57	-	96	98	100
MRSA* only	79	49(a)	9	-	-	0	0	97	97	97	100
Coag neg Staph	139	51(a)	29	-	-	9	38	-	83	62	100
Enterococcus species	84	-	-	69(c)	92	94	-	-	26(c)	-	88(b)

**FIRST ISOLATE METHOD:** For the purpose of guiding clinical decisions about empiric therapy of initial infections, only the first isolate of a given species per patient, irrespective of body site, antimicrobial susceptibility profile, or other phenotypic characteristics is included in data.

\*Includes both community and hospital associated isolates

Aerobic Organisms  Gram NEGATIVE	Range of Isolates	Amikacin	Ampicillin	Amp/Sulbactam	Aztreonam	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Gentamicin	Meropenem	Nitrofurantoin (c)	Pip/Tazo	Tobramycin	Trimeth/sulfa
	#	%	%	%	%	%	%	%	%	%	%	%	%	%	%
Escherichia coli (d)	205	99	46	54	92	85	93	91	66	89	100	90	94	90	66
Enterobacter cloacae complex	31	100	-	-	79	0	94	77	97	94	97	16	79	94	90
Klebsiella pneumoniae (d)	113	100	0	78	92	87	94	91	91	96	99	25	92	93	88
Pseudomonas aeruginosa	76	97	-	-	-	-	95	-	87	87	99	-	86	99	-
Proteus mirabilis	38	100	61	66	78	76	79	79	61	82	100	0	100	84	63

(a) Tested for inducible clindamycin resistance (D Test)

(b) 10 VRE

(c) Tested only on urine isolates

(d) 11 Extended Spectrum Beta Lactamase (ESBL) producers (includes community and hospital acquired): 6 E. coli, 5 K. pneumoniae

Created by: Layla Santiago MT(ASCP), Microbiology Supervisor & Lisa Hirt, Laboratory Resources Coordinator 08/2014

Approved by: Steven Hickerson, MD, Medical Director of Infection Prevention & Amy Beasley, RN, MSN, CPHQ, CIC, Director of Infection Prevention